In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease Cancelling Technology-driven drug pipeline. He speaks to the company’s decade-plus of experience helping pharmaceutical companies understand the biological mechanisms behind some of their most successful medicines, as well as the collaboration between the company’s neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals, to identify novel therapeutic targets for an undisclosed neurodegenerative disease.
